BH3 profiling, a technique developed to predict relative dependency on BCL-2, MCL-1, and BCL-xL, has been shown to be useful in predicting responses of patients with AML after treatment with venetoclax, as well as highlighting potential resistance mechanisms88. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.